Table 1.
Frequencies of SARS-CoV-2 Serology and Virology Tests Completed
| … | Serology Tests | Virology Tests | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Tests Completed | Tests Completed | |||||||||
| No. | 1, No. (%) | 2, No. (%) | 3, No. (%) | ≥4, No. (%) | No. | 1, No. (%) | 2, No. (%) | 3, No. (%) | ≥4, No. (%) | |
| Total | 745 | 246 (33.0) | 139 (18.7) | 116 (15.6) | 244 (32.8) | 918 | 189 (20.6) | 179 (19.5) | 182 (19.8) | 368 (40.1) |
| Age | ||||||||||
| 2–4 y | 100 | 39 (39.0) | 14 (14.0) | 16 (16.0) | 31 (31.0) | 145 | 34 (23.5) | 34 (23.5) | 19 (13.1) | 58 (40.0) |
| 5–11 y | 332 | 116 (34.9) | 60 (18.1) | 49 (14.8) | 107 (32.2) | 414 | 74 (17.9) | 77 (18.6) | 94 (22.7) | 169 (40.8) |
| 12–17 y | 313 | 91 (29.1) | 65 (20.8) | 51 (16.3) | 106 (33.9) | 359 | 81 (22.6) | 68 (18.9) | 69 (19.2) | 141 (39.3) |
| Sex at birth | ||||||||||
| Female | 385 | 122 (31.7) | 62 (16.1) | 69 (17.9) | 132 (34.3) | 475 | 100 (21.1) | 86 (18.1) | 105 (22.1) | 184 (38.7) |
| Race | ||||||||||
| White | 611 | 190 (31.1) | 113 (18.5) | 96 (15.7) | 212 (34.7) | 757 | 149 (19.7) | 143 (18.9) | 153 (20.2) | 312 (41.2) |
| Black | 59 | 24 (40.7) | 14 (23.7) | 8 (13.6) | 13 (22.0) | 60 | 13 (21.7) | 14 (23.3) | 10 (16.7) | 23 (38.3) |
| Native Hawaiian/Pacific Islander | 3 | 0 (0.0) | 1 (33.3) | 0 (0.0) | 2 (66.8) | 3 | 0 (0.0) | 0 (0.0) | 1 (33.3) | 2 (66.7) |
| American Indian/Alaska Native | 2 | 0 (0.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 3 | 2 (66.7) | 1 (33.3) | 0 (0.0) | 0 (0.0) |
| Asian | 25 | 11 (44.0) | 2 (8.0) | 6 (24.0) | 6 (24.0) | 36 | 9 (25.0) | 9 (25.0) | 4 (11.1) | 14 (38.9) |
| Other | 29 | 11 (37.9) | 6 (20.7) | 5 (17.3) | 7 (24.1) | 39 | 11 (28.2) | 8 (20.5) | 7 (18.0) | 13 (33.3) |
| Ethnicity | ||||||||||
| Hispanic/Latino | 49 | 19 (38.8) | 6 (12.2) | 11 (22.5) | 13 (26.5) | 51 | 9 (17.7) | 7 (13.7) | 13 (25.5) | 22 (43.1) |
| Not Hispanic/Latino | 679 | 221 (32.5) | 129 (19.0) | 105 (15.5) | 224 (33.0) | 852 | 178 (20.9) | 168 (19.7) | 163 (19.1) | 343 (40.3) |
No. refers to the total number of participants completing either serology or virology tests; No. (%) refers to the number of participants who completed either 1, 2, 3, or ≥4 tests. All column proportion differences were nonsignificant.
Abbreviation: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.